Chronic Obstructive Pulmonary Disease vs Asthma
Chronic Obstructive Pulmonary Disease and Asthma are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.
Chronic Obstructive Pulmonary Disease vs Asthma at a glance
- Chronic Obstructive Pulmonary Disease: Progressive, largely irreversible airflow limitation from chronic bronchitis and/or emphysema.
- Asthma: Chronic reversible airway inflammation with episodic bronchoconstriction.
Keep comparing — start your free trial
You've used your 2 free previews. Create your free account to see the full Chronic Obstructive Pulmonary Disease vs Asthma comparison — plus all 514 diagnosis outlines, 6,400+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.
Side-by-side comparison
| Feature | Chronic Obstructive Pulmonary Disease | Asthma |
|---|---|---|
| At a glance | Progressive, largely irreversible airflow limitation from chronic bronchitis and/or emphysema. | Chronic reversible airway inflammation with episodic bronchoconstriction. |
| Classic presentation | Hoover sign (paradoxical inward movement of lower ribs on inspiration), 'tripod' posture, prolonged expiration.; Chronic productive cough (chronic bronchitis: ≥3 months/year × 2 years); Progressive exertional dyspnea (mMRC scale); Wheezing, chest tightness; Frequent respiratory infections, exacerbations; Barrel chest, hyperresonance to… | Wheezing that improves with short-acting beta-agonist; nocturnal cough; symptom relief between episodes.; Episodic wheeze, cough (often nocturnal), chest tightness, dyspnea; Triggered by allergens, exercise, cold air, viral URIs, NSAIDs, beta-blockers, emotional stress; Diurnal variation: worse at night and early morning; Expiratory… |
| Workup / key labs | GOLD 2024: symptoms + risk factor exposure + post-bronchodilator FEV1/FVC <0.7. Severity by FEV1 % predicted; clinical group (E, A, B) by symptoms (mMRC, CAT) and exacerbation history.; Alpha-1 antitrypsin level (once per lifetime, all COPD patients per GOLD); ABG if severe disease or exacerbation (hypoxia, hypercapnia); CBC… | GINA: history of variable respiratory symptoms + confirmed variable expiratory airflow limitation (bronchodilator reversibility, methacholine positivity, or PEF variability).; CBC (eosinophilia supports allergic phenotype); Total IgE and allergen-specific IgE if considering biologics or ABPA; FeNO (fractional exhaled nitric oxide) —… |
| Imaging | CXR — hyperinflation (flattened diaphragms, >9 posterior ribs visible), increased AP diameter, bullae; CT chest — emphysema pattern (centrilobular, panlobular, paraseptal), exclude lung cancer; required for lung volume reduction or transplant evaluation; ECG — right axis deviation, P pulmonale, multifocal atrial tachycardia | CXR — usually normal or hyperinflation; obtain to exclude alternative diagnoses or complications (pneumothorax, pneumonia); HRCT if bronchiectasis or alternative diagnosis suspected |
| First-line treatment | Smoking cessation — single most important intervention; reduces rate of FEV1 decline; Pulmonary rehabilitation for mMRC ≥2 or after exacerbation; Vaccinations: annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID-19, RSV (age ≥60), Tdap; GOLD Group A (low symptoms, low exacerbation risk): bronchodilator — short- or long-acting;… | GINA 2024 has eliminated SABA-only treatment; all adults and adolescents should receive ICS-containing therapy; Step 1-2 (mild): low-dose ICS-formoterol PRN (preferred 'MART' approach) — budesonide-formoterol or beclomethasone-formoterol; Step 3 (moderate): low-dose ICS-LABA daily + ICS-formoterol PRN as reliever; Step 4: medium-dose… |
Drill Chronic Obstructive Pulmonary Disease vs Asthma questions on FirstPassPA
Turn this comparison into retention. 6,400+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Try today's free questionEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.